Lower-limb veins are thicker and vascular reactivity is decreased in a rat PCOS model: concomitant vitamin D3 treatment partially prevents these changes

Am J Physiol Heart Circ Physiol. 2014 Sep 15;307(6):H848-57. doi: 10.1152/ajpheart.01024.2013. Epub 2014 Jul 11.

Abstract

Polycystic ovary syndrome (PCOS) causes vascular damage to arteries; however, there are no data for its effect on veins. Our aim was to clarify the effects of dihydrotestosterone (DHT)-induced PCOS both on venous biomechanics and on pharmacological reactivity in a rat model and to test the possible modulatory role of vitamin D3 (vitD). PCOS was induced in female Wistar rats by DHT treatment (83 μg/day, subcutaneous pellet). After 10 wk, the venous biomechanics, norepinephrine (NE)-induced contractility, and acetylcholine-induced relaxation were tested in saphenous veins from control animals and from animals treated with DHT or DHT with vitD using pressure angiography. Additionally, the expression levels of endothelial nitric oxide synthase (eNOS) and cyclooxygenase (COX-2) were measured using immunohistochemistry. Increased diameter, wall thickness, and distensibility as well as decreased vasoconstriction were detected after the DHT treatment. Concomitant vitD treatment lowered the mechanical load on the veins, reduced distensibility, and resulted in vessels that were more relaxed. Although there was no difference in the endothelial dilation tested using acetylcholine (ACh), the blocking effect of N(G)-nitro-l-arginine methyl ester (l-NAME) was lower and was accompanied by lower COX-2 expression in the endothelium after the DHT treatment. Supplementation with vitD prevented these alterations. eNOS expression did not differ among the three groups. We conclude that the hyperandrogenic state resulted in thicker vein walls. These veins showed early remodeling and altered vasorelaxant mechanisms similar to those of varicose veins. Alterations caused by the chronic DHT treatment were prevented partially by concomitant vitD administration.

Keywords: animal model; dihydrotestosterone; polycystic ovary syndrome; venous remodeling; vitamin D.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cholecalciferol / pharmacology*
  • Cyclooxygenase 2 / metabolism
  • Dihydrotestosterone
  • Disease Models, Animal
  • Female
  • Lower Extremity / blood supply*
  • Nitric Oxide Synthase Type III / metabolism
  • Polycystic Ovary Syndrome / chemically induced
  • Polycystic Ovary Syndrome / metabolism
  • Polycystic Ovary Syndrome / pathology
  • Polycystic Ovary Syndrome / physiopathology*
  • Rats
  • Rats, Wistar
  • Saphenous Vein / drug effects*
  • Saphenous Vein / metabolism
  • Saphenous Vein / pathology
  • Saphenous Vein / physiopathology
  • Vasoconstriction / drug effects*
  • Vasoconstrictor Agents / pharmacology
  • Vasodilation / drug effects*
  • Vasodilator Agents / pharmacology
  • Venous Pressure / drug effects

Substances

  • Vasoconstrictor Agents
  • Vasodilator Agents
  • Dihydrotestosterone
  • Cholecalciferol
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat
  • Cyclooxygenase 2
  • Ptgs2 protein, rat